MannKind

Why Shares of MannKind Were Up Wednesday
Why Shares of MannKind Were Up Wednesday
Motley Fool
MannKind
earnings
United Therapeutics
Flag link:
If at first... pharma’s most drawn-out development timelines revealed
If at first... pharma’s most drawn-out development timelines revealed
EP Vantage
Kyowa Kirin
Takeda
Eiger BioPharmaceuticals
AstraZeneca
Teva Pharmaceutical
Bavarian Nordic
Halozyme
Novartis
MannKind
drug development
Flag link:
After buying in candidate, Mannkind wraps up phase 1 trial of inhaled lung infection prospect
After buying in candidate, Mannkind wraps up phase 1 trial of inhaled lung infection prospect
Fierce Pharma
MannKind
clofazimine
FDA
bacterial lung infections
clinical trials
Flag link:
MannKind Acquires Wearable Insulin Device from Zealand Pharma
MannKind Acquires Wearable Insulin Device from Zealand Pharma
Medical Devices and Diagnostics Industry
MannKind
Zealand Pharma
V-Go
insulin
diabetes
devices
Medtech
Flag link:
FDA declines to approve United-MannKind's lung disease therapy
FDA declines to approve United-MannKind's lung disease therapy
Yahoo/Reuters
MannKind
United Therapeutics
Tyvaso
FDA
PAH
Flag link:
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
BioSpace
MannKind
United Therapeutics
PAH
PH-ILD
FDA
priority review
Tyvaso
Flag link:
Five Collaborations Unlocking Faster Drug Development this Week
Five Collaborations Unlocking Faster Drug Development this Week
BioSpace
drug development
MannKind
Thirona Bio
pulmonary fibrosis
Oyster Point Pharma
Adaptive Phage Therapeutics
ophthalmic
Takeda
Codexis
ALX Oncology
Eli Lilly
clinical trials
BeiGene
Shoreline Biosciences
oncology
Flag link:
Why MannKind Stock Crushed it Monday
Why MannKind Stock Crushed it Monday
Motley Fool
MannKind
ADA
diabetes
insulin
Afrezza
inhaled insulin
Flag link:
Why MannKind Is Up Big Today
Why MannKind Is Up Big Today
Motley Fool
MannKind
inhaled insulin
Afrezza
Flag link:
MannKind (MNKD) Q4 Revenues Rise 254%; Achieves First Ever Qtr Afrezza Gross Profit
MannKind (MNKD) Q4 Revenues Rise 254%; Achieves First Ever Qtr Afrezza Gross Profit
Street Insider
MannKind
earnings
Afrezza
Flag link:
FDA’s OPDP Warns MannKind for Facebook Post
FDA’s OPDP Warns MannKind for Facebook Post
RAPS.org
Afrezza
warning letter
FDA
OPDP
Facebook
social media
diabetes
MannKind
Flag link:
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Endpoints
MannKind
United Therapeutics
PAH
Treprostinil
Flag link:
Can MannKind Corporation Avert Bankruptcy?
Can MannKind Corporation Avert Bankruptcy?
Motley Fool
MannKind
earnings
Afrezza
Flag link:
MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase
MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase
Street Insider
MannKind
TreT
FDA
PAH
Flag link:
MannKind Q1 Results: The Good, the Bad, and the Ugly
MannKind Q1 Results: The Good, the Bad, and the Ugly
Motley Fool
MannKind
earnings
Flag link:
Why MannKind Corporation Stock Broke Down in April
Why MannKind Corporation Stock Broke Down in April
Motley Fool
MannKind
Flag link:
3 Bright Spots in MannKind Corporation's Q4 Update
3 Bright Spots in MannKind Corporation's Q4 Update
Motley Fool
MannKind
earnings
Flag link:
Why MannKind Corporation Stock Is Falling Back to Earth Today
Why MannKind Corporation Stock Is Falling Back to Earth Today
Motley Fool
MannKind
diabetes
Afrezza
Flag link:
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Motley Fool
diabetes
Senseonics
Lexicon Pharmaceuticals
MannKind
Flag link:
Why MannKind Corporation Jumped Higher Today
Why MannKind Corporation Jumped Higher Today
Motley Fool
MannKind
diabetes
Afrezza
Flag link:

Pages